Claims
- 1. A compound of formula I or pharmaceutically acceptable salts thereof wherein:
- Q is
- (a) --O--, or
- (b) --CH.sub.2 --;
- R.sub.1 is
- (a) --N.dbd.C(SCH.sub.3)(NH-phenyl),
- (b) --N.dbd.C(SCH.sub.3)(NHCH.sub.2 CH.sub.2 -phenyl),
- (c) --N.dbd.C(SCH.sub.3)(NH-4-nitrophenyl),
- (d) --N.dbd.C(SCH.sub.2 CH.sub.3)(NHCH.sub.2 CH.sub.2 -phenyl),
- (e) --SO.sub.2 NH(3-methoxyphenyl),
- (f) --SO.sub.2 NH(3-methylphenyl), or
- (g) --N.dbd.C(NH.sub.2)(phenyl); with the following provisos:
- (a) where Q is --O--, R.sub.1 and R.sub.2 are other than (g), and
- (b) where Q is --CH.sub.2 --, R.sub.1 and R.sub.2 are other than (a)-(f).
- 2. A compound of formula 1 according to claim 1 which is
- a) Dimethyl N,N"-(oxydi-4,1-phenylene)bis�N'-(phenyl)carbamimidothioate!,
- b) Dimethyl N,N"-(oxydi-4,1-phenylene)bis�N'-(2-phenylethyl) carbamimidothioate!,
- c) Dimethyl N,N"-(oxydi-4,1-phenylene)bis �N'-(4-nitrophenyl) carbamimidothioate!,
- d) Diethyl N,N"-(oxydi-4,1-phenylene)bis�N'-(2-phenylethyl)carbamimidothioate!,
- e) Bis�N-(3-methoxyphenyl)aminosulfonyl!(oxydi-4,1-phenylene),
- f) Bis�N-(3-methylphenyl)aminosulfonyl!(oxydi-4,1-phenylene), or
- g) N,N"-(Methylenedi-4,1-phenylene)bis�benzenecarboximidamide!.
- 3. A method for treating herpes virus infection in patients which comprises topically administering to the herpetic lesion on the skin of said patients an effective amount of a compound of formula III ##STR32## or pharmaceutically acceptable salts thereof wherein: A is
- (a) --O--,
- (b) --CH.sub.2, or
- (c) --S(.dbd.O).sub.2 --;
- R.sub.3 and R.sub.4 are the same and are
- (a) --N.dbd.C(SCH.sub.3)(NH-phenyl),
- (b) --N.dbd.C(SCH.sub.3)(NHCH.sub.2 CH.sub.2 -phenyl),
- (c) --N.dbd.C(SCH.sub.3)(NH-4-nitrophenyl),
- (d) --N.dbd.C(SCH.sub.2 CH.sub.3)(NHCH.sub.2 CH.sub.2 -phenyl),
- (e) --SO.sub.2 NH(3-methoxyphenyl),
- (f) --SO.sub.2 NH(3-methylphenyl),
- (g) --N.dbd.C(NH.sub.2)(phenyl),
- (x) --NHC(.dbd.O)(2-furyl),
- (i) --NHC(.dbd.S)NHCH.sub.2 CH.sub.2 -phenyl,
- (j) --NHC(.dbd.S)NH(4-nitrophenyl),
- (k) --OCH.sub.2 (4-bromophenyl),
- (l) --OCH.sub.2 (4-chlorophenyl),
- (m) --OCH.sub.2 (4-fluorophenyl),
- (n) --OCH.sub.2 (4-pyridyl),
- R.sub.3 and R.sub.4 are different and are
- (o) --OH,
- (p) --OCH.sub.2 (4-chlorophenyl), or
- (q) --OCH.sub.2 (4-nitrophenyl); with the following provisos:
- (a) where A is --O--, R.sub.3 and R.sub.4 are other than (k)-(q),
- (b) where A is --CH.sub.2 --, R3 and R.sub.4 are (g) or (j), and
- (c) where A is --S(.dbd.O).sub.2 --, R.sub.3 and R.sub.4 are other than (a)-(j).
- 4. A method for treating herpes virus according to claim 3, wherein the compound of formula III is
- a) Dimethyl N,N"-(oxydi-4,1-phenylene)bis�N'-(phenyl)carbamimidothioate!,
- b) Dimethyl N,N"-(oxydi-4,1-phenylene)bis�N'-(2-phenylethyl) carbamimidothioate!,
- c) Dimethyl N,N"-(oxydi-4,1-phenylene)bis�N'-(4-nitrophenyl) carbamimidothioate!,
- d) Diethyl N,N"-(oxydi-4,1-phenylene)bis �N'-(2-phenylethyl)carbamimidothioate!,
- e) Bis�N-(3-methoxyphenyl)aminosulfonyl!(oxydi-4,1-phenylene),
- f) Bis�N-(3-methylphenyl)aminosulfonyl!(oxydi-4,1-phenylene),
- g) N,N"-(Methylenedi-4,1-phenylene)bis�benzenecarboximidamide!,
- h) N,N"-(Oxydi-4,1-phenylene)bis(2-furancarboxamide),
- i) N,N"-(Oxydi-4,1-phenylene)bis�N'-(2-phenylethyl)thiourea!,
- j) N,N"-(Oxydi-4,1-phenylene)bis �N'-(4-nitrophenyl)thiourea!,
- k) N,N"-(Methylenedi-4,1-phenylene)bis �N'-(4-nitrophenyl)thiourea!,
- l) Bis(4-bromobenzyloxy)(sulfonyldi-4,1-phenylene),
- m) Bis(4-chlorobenzyloxy)(sulfonyldi-4,1-phenylene),
- n) Bis(4-fluorobenzyloxy)(sulfonyldi-4,1-phenylene),
- o) Bis�(4-pyridyl)methoxy!(sulfonyldi-4,1-phenylene),
- p) (4-Chlorobenzyloxy)hydroxy(sulfonyldi-4,1-phenylene), or
- q) Hydroxy(4-nitrobenzyloxy)(sulfonyldi-4,1-phenylene).
- 5. The method of claim 3 wherein the herpes virus infection is herpes simplex type-1.
- 6. The method of claim 3 wherein the herpes virus infection is herpes simplex type-2.
- 7. The method of claim 3 wherein the herpes virus infection is varicella zoster virus.
- 8. The method of claim 3 wherein the effective amount is administered topically in a pharmaceutical composition.
- 9. A pharmaceutical composition for treating herpes viral infections in patients which comprises a compound of formula I according to claim 1 and a pharmaceutically acceptable carrier.
- 10. The pharmaceutical composition of claim 9 wherein said compound of formula I is present in an amount of about 0.05% to about 25% by weight.
- 11. The pharmaceutical composition of claim 9 wherein said compound of formula I is present in an amount of about 0.1% to about 10% by weight.
CROSS-REFERENCE TO RELATED APPLICATION
This application claims the benefit of the following provisional application: U.S. Ser. No. 60/043,232, filed 10 Apr. 1997, under 35 USC 119(e)(i).
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5500322 |
Tanaka et al. |
Mar 1996 |
|
5679695 |
Wassmundt |
Oct 1997 |
|
Foreign Referenced Citations (7)
Number |
Date |
Country |
0 380 048 A2 |
Aug 1990 |
EPX |
0 498 095 A1 |
Aug 1992 |
EPX |
0519 702 |
Dec 1992 |
EPX |
0611 754 |
Aug 1994 |
EPX |
2290 626 |
Jan 1996 |
GBX |
WO8203390 |
Oct 1982 |
WOX |
WO8800828 |
Feb 1988 |
WOX |
Non-Patent Literature Citations (3)
Entry |
Chemical Abstracts, vol. 90, No. 2, Jan. 8, 1979. |
Patent Abstracts of Japan, vol. 5, No. 184, Nov. 21, 1981. |
Chemical Abstracts, vol. 126, No. 17, Apr. 28, 1997. |